A quick starting moment

• Tell me briefly what event or trigger prompted your team to start this medication-safety project and when it occurred.
• How many inpatient beds and active prescribers would you expect to include in an initial pilot? Options: <50 beds / <20 prescribers, 50–150 beds / 20–75 prescribers, 151–400 beds / 75–200 prescribers, >400 beds / >200 prescribers
• Who in your organization typically signs off on the scope and success criteria for pilots like this? Options: Chief Pharmacy Officer, VP Quality or Chief Quality Officer, CMIO/Informatics Director, Patient Safety Officer, Other
• Describe the single outcome your leadership will call success for a pilot, and include the numeric target if there is one.

Where medication safety causes real pain

• Name the one medication-safety failure that would make you stop this project immediately if it recurred during a pilot.
• How often do high-severity medication alerts currently fire per 1,000 admissions in the service line you would pilot? Options: <1, 1–5, 6–15, >15, Unknown
• Which clinician groups override the most alerts today, and which workflows do those overrides most affect? Options: Attending physicians, Residents/trainees, Nurse practitioners/physician assistants, Pharmacists, Other
• Estimate the financial or regulatory impact from your most recent sentinel medication event, using ranges if needed. Options: < $10k or minor reprimand, $10k–$100k or internal remediation, $100k–$1M or regulatory notice, > $1M or CMS/JCAHO action, Prefer not to quantify
• Who on your team feels the greatest pressure when these events occur, operationally or legally? Options: Chief Pharmacy Officer, VP Quality, CMIO, Risk/Legal, Patient Safety Officer, Other

Where current controls quietly fail

• When a guideline or formulary change happens overnight, what breaks first in your medication guidance and alerting workflow?
• Do you currently have a defined process to update clinical decision support content within 72 hours of a major guideline change? Options: Yes, documented and practiced, Partially, ad hoc team response, No, updates take weeks or months, Unsure
• Which systems must be integrated for the platform to evaluate medications in real time at your site? Select all that apply. Options: EHR orders and meds module, Medication administration record (MAR), Pharmacy dispense system, Clinical data repository / HIE, Identity and access system, Other
• List the roles responsible today for alert tuning, and give the approximate FTEs or percentage time allocated to that work.
• Rate your medication and order data cleanliness and accessibility for mapping external content on a 1 to 5 scale, where 5 means ready for real-time matching. Options: 1, 2, 3, 4, 5
• If real-time APIs are not available for order checks, would lack of those APIs stop the pilot from proceeding? Options: Yes, we require real-time APIs, Not necessarily, we can run a near-real-time pilot, Only if no other integration path exists, Unsure

Who else is on the shortlist

• Name the other external vendors, incumbent tools, or internal projects your team is actively considering for this capability.
• What would have to be true about your current approach for your team to decide to keep it instead of switching to an external partner?
• Do any internal teams have an active proposal to build this capability in-house, and if so who would lead that effort? Options: Yes, clinical informatics, Yes, pharmacy informatics, Yes, IT/Integration team, No internal build proposed, Unsure
• List the deal-breaker gaps you see in the incumbent or internal options that would push you to select a new partner.
• If you stayed with the incumbent or built internally, what concrete change would be required within 6 months to avoid switching vendors?

Outcomes that make the CFO and CPO sign

• Identify the single metric your chief pharmacy officer or VP quality will use to determine this pilot is worth expanding enterprise-wide. Options: Alert override rate, Adverse drug event rate, Time saved per clinician, Regulatory deficiency closed, Other
• Within how many weeks after pilot start would leadership expect to see measurable change against that metric? Options: <4 weeks, 4–8 weeks, 9–12 weeks, >12 weeks, No firm expectation
• Specify the numeric acceptance criteria and any linked thresholds that must be hit for you to consider enterprise rollout.
• Would achieving a reduction in override rates to under 40% alone be sufficient to trigger expansion, or do you require linked clinical outcome improvements? Options: Override reduction alone is sufficient, Require linked clinical outcome improvement, Need both plus clinician time savings, Unsure
• Identify the approvals or committees that would still need to sign off before contract signature even if the pilot meets targets.

Integration, timelines, and technical gates

• Tell us which integration gap or missing connector, if not resolved, would force you to cancel the pilot.
• Specify the APIs, message feeds, or interfaces your EHR and pharmacy teams must expose for the pilot to function as intended. Options: Order entry API, Medication master/ formulary feed, Administration events/MAR feed, Pharmacy dispense feed, Patient demographic feed, Other
• Are there scheduled batch loads, daily cutoffs, or record-locking behaviors that could prevent real-time decision support during peak hours? Options: Yes, regular nightly batches, Yes, daytime locking windows, No, system supports real-time, Unsure
• State the IT integration team that would own the work and their estimated available hours per week for this project.
• Rate your data mapping readiness for medication codes and orderables on a 1 to 5 scale. Options: 1, 2, 3, 4, 5
• Can legal or compliance approve the required data-sharing and integration agreements within your target go-live window? Options: Yes, No, Only with modifications, Unsure

Who signs and who tunes after go-live

• Point to the role that will own post-deployment safety reviews and the tuning cadence, and say whether that role can change alerts without committee approval. Options: Pharmacy director, full authority, Clinical informatics lead, needs committee, Patient safety officer, advisory only, Other
• At what cadence do you expect executive-level outcome reviews during the pilot and through the first year of rollout? Options: Weekly, Biweekly, Monthly, Quarterly, On-demand
• Provide the stakeholder groups you require in tuning sprints and identify who has final approval to suppress classes of low-severity alerts. Options: Pharmacy, Informatics/CMIO, Nursing leadership, Quality, Risk/Legal, Other
• What escalation path do you expect when a clinician reports a harmful near-miss tied to a decision support recommendation?
• Would the clinician safety committee's refusal to endorse external content updates stop deployment? Options: Yes, deployment would pause, No, local overrides can be used, Only temporarily until concerns are resolved, Unsure

Agreeing next steps without wasted time

• Define the earliest pilot start date your team could commit to with the current resource picture. Options: Within 2 weeks, 2–4 weeks, 5–8 weeks, >8 weeks, Not ready to commit
• Select the people we should invite to the kickoff so decisions on scope, tuning, and success metrics can be made there. Options: Chief Pharmacy Officer, VP Quality, CMIO/Informatics Director, Pharmacy Informatics Lead, IT Integration Lead, Nursing Lead, Other
• Describe the measurement method you will use for clinician time impact during the pilot and the role accountable for collecting that data.
• Point out the top three risks you require mitigation for before signing a Statement of Work.
• Assuming we can provide a 6-week technical integration and a 12-week tuning window that meets your acceptance criteria, are you prepared to sign a pilot agreement within the same month? Options: Yes, ready to sign, Yes, with minor approvals, Not without further evaluation, No, not ready

• Clinical Workflow Walkthrough

• Confirm the current state and its cost to your team
• You confirm the current alert fatigue and workflow friction statement matches what your clinicians experience.
• Provide two representative patient cases and the list of EHR user roles to test in the next session.
• Agree pilot acceptance criteria and target metrics
• You agree the demonstrated workflows deliver the operational outcome of fewer low-value interruptions and align with the pilot acceptance metrics.
• Execute the two validated clinical scenarios in a test EHR environment and deliver recordings plus alert logs and tuning rule snapshots before the follow-up.
• Walk through Scenario A, clinician order-entry perspective
• Confirm pilot acceptance criteria including target override rate, acceptable alert latency, and clinician time impact thresholds.
• You identify any remaining evidence needed to approve a pilot, including performance and reporting requirements.
• Identify the decision makers and required stakeholders who must attend the pilot validation review.
• Walk through Scenario B, cross-role handoff and nurse administration
• Review tuning rules, content update cadence, and analytics signals
• Validate the demonstrated future state

• Clinical Workflow Walkthrough
• Clinical Workflow Walkthrough Deck
• Clinical Workflow Solution Brief

• meeting
• slides
• document

• EHR Contextual Trigger Integration
• Medication Interaction Rule Set Deployment
• Dose Verification and Range Check Implementation
• Diagnostic Decision Tree Activation
• Imaging Appropriateness Criteria Enforcement
• Antimicrobial Stewardship Order Checks
• Alert Tuning and Severity Suppression
• Clinical Content 72‑Hour Update Service
• Real‑time Override and Outcome Analytics Dashboard
• Order Set and Protocol Synchronization
• Latency and Runtime Performance Optimization
• Clinician Workflow Training and Go‑Live Support
• Audit Logging and Intervention Trace Export
• Rule Versioning and Rollback Controls

EHR Contextual Trigger Integration

• Which EHR screens (for example CPOE order entry, medication administration record, or reconciliation) should trigger contextual guidance for medication safety? Options: CPOE order entry, Medication administration record (MAR), Medication reconciliation, Problem list / allergy screen, Other
• Do you currently have an integration endpoint that exposes real-time FHIR resources (for example MedicationRequest, Observation) or HL7 v2 feeds we must consume? Options: FHIR resources available, HL7 v2 feeds available, Both FHIR and HL7 v2, No real-time endpoint available
• Who on your informatics team will be the API owner for testing the EHR trigger (provide name, role, and email)?
• How many distinct hospital locations or EHR instances must the trigger integration cover for the initial pilot (for example single hospital ED, multi-hospital system)? Options: 1 (single site), 2-3 sites, 4-10 sites, More than 10
• When should the trigger be active during the clinician workflow (for example on order save, on order sign, on post-verification in pharmacy)? Options: On order save, On order sign, Post-verification in pharmacy, On medication administration, Other
• Describe any existing EHR performance constraints we should design for (for example max API response 200 ms, max concurrent calls per second).

Medication Interaction Rule Set Deployment

• Which inpatient service line do you want to pilot the interaction rule set on (for example adult medical-surgical, pediatrics, ICU)? Options: Adult medical-surgical, Intensive care unit (ICU), Emergency department (ED), Pediatrics, Other
• Do you have an existing formulary or local interaction exceptions list that must be applied to the deployed rule set? Options: Yes, formulary list, Yes, exceptions list, Both, No
• Who will be the clinical owner for rule acceptance decisions (title and contact) during pilot tuning?
• How many interaction categories (for example major, moderate, minor) do you require and what override threshold will you accept for a major interaction alert? Options: Major/Moderate/Minor (default), Major/Moderate only, Custom categories
• Specify the source lists or coding systems your EHR uses for medications and interactions (for example RxNorm, local drug IDs). Options: RxNorm, Local drug IDs, Other coding system
• Identify any existing clinical decision support (CDS) rules that must remain disabled or reconciled to avoid duplicate interaction alerts.

Dose Verification and Range Check Implementation

• Which patient populations need dose-range checks (for example neonates, renal impairment, weight-based dosing units)? Options: Adults, Pediatrics, Neonates, Renal impairment, Other
• Do you maintain a dosing reference (for example local dosing table, pharmacy protocol spreadsheet) that we should import as the authoritative ranges? Options: Yes, dosing table, Yes, pharmacy protocols, No, use defaults
• Who will provide patient-specific inputs required for dose calculations (for example current weight, latest creatinine, dialysis status) and via which EHR field names?
• How do you want weight-based doses evaluated when documented weight is older than a threshold (for example older than 24 hours)? Options: Use regardless of age, Require weight within 24 hours, Prompt clinician to confirm weight, Other
• When a dose exceeds a hard stop threshold, what action should occur in the EHR workflow (for example block order, require pharmacist cosignature, fire soft alert)? Options: Hard stop (block), Require pharmacist cosign, Soft alert with override reason, Other
• Provide examples of three high-risk medications at your institution where dose-range checking is mandatory (drug name and typical dosing range).

Diagnostic Decision Tree Activation

• Which diagnostic workflows should activate decision trees (for example chest pain in ED, fever in oncology, sepsis screening)? Options: Chest pain (ED), Fever in oncology, Sepsis screening, Stroke pathway, Other
• Do you have local order sets or pathway documents we must reference when building the decision tree steps (please attach or name the document ID)? Options: Yes, local order sets, Yes, pathway documents, No, use evidence-based defaults
• Who is the clinical SME (subject matter expert) that will approve branching logic for the decision tree during build and tuning?
• How many decision points should be visible to clinicians before requiring an expanded view (for example show 3 items then expand)? Options: Show 1-2 then expand, Show 3 then expand, Show all
• Describe required provenance for each decision node (for example cite guideline name and date such as Surviving Sepsis Campaign 2021) that must be displayed in the EHR.
• Identify any regulatory or local compliance constraints that affect diagnostic prompts (for example CMS sepsis measure timing).

Imaging Appropriateness Criteria Enforcement

• Which imaging order types should trigger appropriateness checks (for example CT with contrast, MRI spine, plain films)? Options: CT with contrast, CT without contrast, MRI, X-ray, Ultrasound, Other
• Do you require the system to reference national appropriateness criteria (for example ACR Appropriateness Criteria) or local radiology protocols? Options: National criteria (ACR), Local radiology protocols, Both
• Who will own adjudication of overridden appropriateness recommendations (radiology director, ordering clinician, or peer review)? Options: Radiology director, Ordering clinician, Peer review committee, Other
• How should the system surface alternatives when an imaging order is flagged (for example suggest alternative modality, require documented clinical indication)? Options: Suggest alternative modality, Require documented indication, Auto-fill preauthorization form, Other
• When imaging orders are modified or canceled due to appropriateness checks, what audit or notification is required (for example email to ordering provider, radiology log)? Options: Email notification, EHR task message, Radiology log only, No notification
• Provide three example imaging scenarios from your facility where appropriateness enforcement is high priority (modality and clinical indication).

Antimicrobial Stewardship Order Checks

• Which stewardship checks do you require for the pilot (for example duration alerts, duplicate therapy, IV-to-oral switch)? Options: Duration alerts, Duplicate therapy, IV-to-oral switch, Restricted antimicrobial approval, Other
• Do you maintain an antibiogram or local susceptibility matrix we must reference when suggesting empiric therapy? Options: Yes, antibiogram available, No, do not reference
• Who will approve stewardship thresholds (for example default duration in days for community-acquired pneumonia) during the pilot?
• How should restricted antimicrobial orders be routed (for example require antimicrobial stewardship team approval, require pharmacy verification)? Options: Require stewardship approval, Require pharmacy verification, Soft alert with documentation, Other
• Identify the EHR order attributes we must read to enforce stewardship rules (for example order start date, specimen culture results, allergy list).
• Estimate the target reduction in inappropriate antimicrobial days of therapy (DOT) you expect from the pilot (percentage). Options: <10%, 10-25%, 25-50%, >50%

Alert Tuning and Severity Suppression

• Which clinician roles should be able to tune alert thresholds in production (for example pharmacists, physician informaticists, nursing leaders)? Options: Pharmacists, Physician informaticist, Nursing leadership, Clinical quality team, Other
• Do you want severity suppression rules by patient cohort (for example suppress low-severity in ICU or exclude hospice)? Options: Yes, by cohort, No, universal rules, Only for hospice/palliative
• Who will own weekly tuning sprints and change approvals during the quarter-long tuning period (title and contact)?
• How many incremental tuning windows do you want in the initial quarter (for example weekly, biweekly)? Options: Weekly, Biweekly, Monthly
• Specify the maximum acceptable alert override rate for the pilot that will be used as an acceptance threshold (for example 40% override for interruptive alerts). Options: <20%, <40%, <60%, No target set
• Confirm which alert channels are considered interruptive in your EHR (for example hard stop modal, in-line order warning, passive info banner). Options: Hard stop modal, Inline order warning, Passive banner, Message center only

Clinical Content 72‑Hour Update Service

• Which clinical content types require the 72-hour update SLA (for example drug interaction updates, new guideline advisories, black box warnings)? Options: Drug interaction updates, Guideline advisories, Black box warnings, Order set changes, Other
• Do you require automated push of content changes into your EHR content repository or a staged import for informatics review? Options: Automated push, Staged import for review, Manual updates only
• Who on your clinical editorial or pharmacy team will receive 72-hour change notices (name and role)?
• How should emergency updates be validated in the EHR (for example rapid approval by pharmacy director within 24 hours)? Options: Rapid approval workflow, Auto-apply then review, Hold until next maintenance window
• Provide an example recent guideline change you expect the service to capture within 72 hours (for example new dosing restriction for a medication class).
• Indicate any governance constraints on content changes (for example pharmacy committee sign-off required, physician chair approval). Options: Pharmacy committee sign-off, Physician chair approval, Informatics approval, No additional governance

Real‑time Override and Outcome Analytics Dashboard

• Which outcome metrics must be visible on day one of the dashboard (for example alert override rate, time-to-order completion, ADE — adverse drug event — incidence)? Options: Alert override rate, Time-to-order completion, ADE incidence, Number of suppressed low-severity alerts, Other
• Do you require data latency of near real-time (for example under 5 minutes) or is daily batch acceptable for analytics? Options: Near real-time (<5 min), Near real-time (<60 min), Daily batch
• Who will be the analytics dashboard owner responsible for weekly review and escalation (name and role)?
• How should clinician-level override detail be handled for privacy when exported (for example de-identified, role-level only, full audit with SSO access)? Options: De-identified, Role-level only, Full audit export with restricted access
• Specify which downstream outcomes you want correlated with CDS interventions (for example reduction in harm events, 30-day readmission, pharmacy turnaround time). Options: Reduction in harm events, 30-day readmission, Pharmacy turnaround time, Other
• State the acceptance criteria for the dashboard data coverage and freshness that will constitute 'ready for pilot review'.

Order Set and Protocol Synchronization

• Which order sets require synchronization with the platform during the pilot (for example pneumonia, anticoagulation, perioperative antibiotics)? Options: Pneumonia, Anticoagulation, Perioperative antibiotics, Sepsis order set, Other
• Do you maintain order sets in a central repository we can pull from or must we map from the EHR order set IDs? Options: Central repository available, Map from EHR order set IDs, No central repository
• Who will be responsible for approving synchronized order set changes in your governance process (title and contact)?
• How frequently should order set synchronization occur after go-live (for example daily, weekly, on-demand)? Options: Daily, Weekly, On-demand/manual
• Describe any mapping complexity we should expect (for example duplicate local medication codes, compounded preparations).
• Indicate which protocol updates are out of scope for the pilot and will require a separate SOW (statement of work). Options: Major protocol redesign, Enterprise-wide order set rewrite, Local minor edits only, Other

• decision_readiness
• current_state
• stakeholders
• success_criteria
• desired_state
• gaps
• desired_state
• decision_readiness
• current_state
• success_criteria
• stakeholders
• gaps
• stakeholders
• current_state
• desired_state
• success_criteria
• gaps
• decision_readiness
• decision_readiness
• decision_readiness
• decision_readiness
• decision_readiness

• Non-Disclosure Agreement (NDA)
• Master Services Agreement (MSA)
• Statement of Work (SOW)
• Order Form / Subscription Agreement
• Service Level Agreement (SLA)
• Acceptance & Go-Live Criteria
• Governance & Steering Committee Charter
• Support & Escalation Addendum
• Change Order Agreement
• Data Processing Agreement / HIPAA BAA (conditional)

• Go-live Health Check (week 1-4)
• First Measurement Review (week 4-10)
• Acceptance Gate Review (around day 90)
• Ongoing Outcomes & Tuning Review (monthly for first 3 months, then quarterly)

• Run a quarterly clinician survey to measure perceived alert fatigue and time impact and summarize results.
• Execute the agreed tuning changes and report the outcome in the next checkpoint.
• Run a clinician feedback pulse focused on alerts with the highest override rates and summarize findings.
• Validate and publish the measurement calculation method for override rate and clinician time impact.
• Restate acceptance criteria and numeric targets
• Produce a documented acceptance decision referenced to the targets recorded in Solution Scope, with a named buyer signatory where enterprise governance requires it.
• For any unmet criteria, agree a remediation plan with owners and dates sufficient to close the acceptance loop.
• Confirm the incumbent system's decommissioning plan or read-only retention and the status of data migration or archival.
• Publish the acceptance record including pass/fail per criterion and the named buyer signatory where required.
• Create a remediation tracker for any failed criteria with owners and target resolution dates.
• Execute or confirm the incumbent system wind-down steps and archive or migrate legacy data as documented.
• Trend review for key outcomes
• Ensure alert override rate and adverse drug event rate continue to trend toward or remain within the targets recorded in Solution Scope.
• Keep the tuning backlog prioritized and progressing, with clear owners and dates for the top items.
• Verify content maintenance meets the agreed SLA and log any required catch-up actions.
• Schedule the next tuning window and list the specific rules or content sets to be adjusted.
• Publish the prioritized enhancement request list with expected delivery quarters.
• Re-confirm success criteria and owners
• Confirm the integration endpoints and test environments are stable enough to begin collecting meaningful usage data.
• Identify and assign owners for any go-live defects with committed resolution dates.
• Publish the go-live defect log with owners and target resolution dates.
• Enable agreed monitoring dashboards for usage and error metrics for the first 30 days.
• Present first-run metrics
• Determine whether alert override rate and average clinician time per alert are on track to meet the targets recorded in Solution Scope.
• Document root causes for any gaps and commit to specific tuning or content actions with clear dates.
• Diagnose gaps versus targets
• Tuning actions and results
• Present outcome data against each criterion
• Deployment and integration validation
• Document pass/fail per criterion and rationale
• Agree corrective tuning and timelines
• Open issues and enhancement request backlog
• Early adoption signals and usage patterns
• Content maintenance and SLA adherence
• Open issues and immediate remediation
• Formal acceptance decision and signatory capture
• Confirm data integrity and measurement sources
• Confirm path to acceptance gate
• Incumbent system wind-down confirmation
• Short action wrap-up and next checkpoints
• Agree short-term actions and cadence
• Agree remediation plan for unmet criteria